CIPLA QUALITY CHEMICAL INDUSTRIES LIMITED

May 23, 2017

Cipla Quality Chemical Industries Limited is a state of the art pharmaceutical plant that manufactures the latest Anti-retroviral (ARVs) and Anti-malarial (ACTs) medicines. CiplaQCIL was established in 2005 as a joint venture company between Cipla Ltd of India, the world’s largest manufacturer of generic medicines and Quality Chemicals (QCL) Ltd of Uganda.

Spotlight

Supernus Pharmaceuticals, Inc.

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

OTHER WHITEPAPERS
news image

Sampling Sulfuric Acid

whitePaper | May 6, 2021

While grab sampling in an industrial setting may represent a tiny fraction of a plant’s overall activities, its importance cannot be underestimated. Unfortunately, sometimes the focus on sampling improvements only becomes critical after an incident, an accident or equipment failure. Sampling is an integral part of the manufacturing process, and a safe and reliable sampling regime can improve: Safety, Industrial Hygiene, Sample Quality, A plant’s bottom line.

Read More
news image

LATIN AMERICA PETROCHEMICALS AND CHEMICALS 2019

whitePaper | November 27, 2019

In this challenging environment, it is key for petrochemical and chemical producers to be efficient and to manage closely their production and logistics chains. We live in a world of product abundance as a result of the shale gas revolution, so the market will be taken by those who can be the most competitive. In this respect, the region needs to take advantage of its geological potential, with the pre-salt fields in Brazil and Argentina’s Vaca Muerta developments, as well as Mexico’s injection of funds to Pemex to help the state-oil company recover its past grandeur.

Read More
news image

Chemicals supply chain: how to catch up the race!

whitePaper | December 13, 2019

The chemical industry has enjoyed strong and consistent performance over the last decade. The market is now being affected by new challenges, from increased global competition and changing customer requirements to disruptive new technologies while increased demand for sustainability, safety, and efficiency is changing not only the way companies work, but the products they produce.

Read More
news image

Temperature Control for Chemical Research and Production

whitePaper | November 20, 2022

Precise temperature control has a significant influence on performance and quality in chemical process engineering. The Unistat range of temperature control systems ensure accurate temperatures and stable.

Read More
news image

ADVANCED DEMAND FLEXIBILITY MANAGEMENT

whitePaper | June 22, 2022

California’s electricity system is undergoing rapid transformation on the pathway to 100% renewable power, with the expected high penetration of renewables, electrification of buildings and transportation, and deployment of behind-the-meter (BTM) distributed energy resources (DERs).

Read More
news image

Climate-related Disclosures Report

whitePaper | December 21, 2022

Our 2021 reporting suite brings together NatWest Group’s financial, non-financial and risk performance for the year.

Read More

Spotlight

Supernus Pharmaceuticals, Inc.

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Events